

<https://helda.helsinki.fi>

Granuloma Annulare and Morphea : Correlation with Borrelia burgdorferi Infections and Chlamydia-related Bacteria

Tolkki, Lauri

2018

Tolkki , L , Hokynar , K , Meri , S , Panelius , J , Puolakkainen , M & Ranki , A 2018 , ' Granuloma Annulare and Morphea : Correlation with Borrelia burgdorferi Infections and Chlamydia-related Bacteria ' , Acta Dermato-Venereologica , vol. 98 , no. 3 , pp. 355-360 . <https://doi.org/10.2340/00015555-2831>

<http://hdl.handle.net/10138/233836>

<https://doi.org/10.2340/00015555-2831>

cc_by_nc

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Granuloma Annulare and Morphea: Correlation with *Borrelia burgdorferi* Infections and Chlamydia-related Bacteria

Lauri TOLKKI^{1#}, Kati HOKYNAR^{2#}, Seppo MERI³, Jaana PANELIUS¹, Mirja PUOLAKKAINEN² and Annamari RANKI¹

¹Department of Dermatology, Allergology and Venereal Diseases, University of Helsinki and Center of Inflammation, Helsinki University Central Hospital, ²Department of Virology, and ³Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland

[#]These authors contributed equally to this paper.

A retrospective study of 109 skin biopsies with granuloma annulare (GA) or morphea histology from patients with suspected tick bite was performed. Biopsies were tested for cutaneous *Borrelia burgdorferi* DNA using PCR. The same biopsies were analysed for tick-borne novel agents, *Chlamydia*-related bacteria (members of the Chlamydiales order), using a PCR-based method. *Borrelia* DNA was detected in 7/73 (9.6%) biopsies with GA and in 1/36 (2.8 %) biopsies with morphea, while Chlamydiales DNA was found in 53/73 (72.6%) biopsies with GA and 25/34 (73.4%) biopsies with morphea. All *Borrelia* DNA-positive GA samples were also positive for Chlamydiales DNA. The Chlamydiales sequences detected in GA were heterogeneous and contained *Waddliaceae* and *Rhabdochlamydiaceae* bacteria, which are also present in *Ixodes ricinus* ticks, while the Chlamydiales sequences detected in morphea closely resembled those found in healthy skin. In conclusion, tick-mediated infections can trigger GA in some cases, while correlation of either *Borrelia* or Chlamydiales with morphea is unlikely.

Key words: granuloma annulare; morphea; *Borrelia burgdorferi*; chlamydia-related bacteria.

Accepted Oct 31, 2017; Epub ahead of print Nov 7, 2017

Acta Derm Venereol 2018; 98: 355–360.

Corr: Lauri Tolkki, Center of Inflammation, Department of Dermatology, Allergology and Venereal Diseases, Helsinki University Central Hospital, PO Box 160, FIN-00029 Helsinki, Finland. E-mail: Lauri.Tolkki@hus.fi

Granuloma annulare (GA) and morphea (localized scleroderma) are skin reactions with unknown aetiology (1–5). One of the possible causative agents is *Borrelia burgdorferi sensu lato*, a spirochete transmitted to humans via tick bites. Although the causal connections between *B. burgdorferi* and GA and morphea have been explored in several studies using various methods, including indirect serological methods and direct detection by PCR, there is no firm evidence of a causative role (6–11).

In addition to *B. burgdorferi sensu lato*, ticks are known to serve as vectors for a number of other animal and human pathogens, such as *Babesia microti*, which causes babesiosis, *Anaplasma phagocytophilum*, which causes human granulocytic anaplasmosis, species of the spotted fever group of *Rickettsiae*, and *Flavivirus*, which causes tick-borne encephalitis (TBE) (12–15).

Recently, *Ixodes ricinus* ticks have also been shown to carry another group of potential human pathogens,

Chlamydia-related bacteria (16–19). They share the characteristic features of the order Chlamydiales: strict intracellular lifestyle, biphasic developmental cycle and a large core-set of genes. The traditional members of the order are the established human pathogens *Chlamydia trachomatis* and *Chlamydia pneumoniae* (genus *Chlamydia*, family *Chlamydiaceae*). During the last 20 years, an increasing number of novel chlamydial species have been described and, currently, 8 additional families are recognized as belonging to the Chlamydiales order. These new families: *Parachlamydiaceae*, *Waddliaceae*, *Simkaniaceae*, *Rhabdochlamydiaceae*, *Criblamydiaceae*, *Piscichlamydiaceae*, *Clavichlamydiaceae* and *Parilichlamydiaceae* are collectively called *Chlamydia*-related bacteria. They were originally detected in various types of environmental samples (e.g. soil and water from various sources), but subsequently also in animals, including arthropods, and humans. Many of them have pathogenic potential (20, 21), and their reservoirs, vectors and transmission routes have been widely investigated, but have mainly remained obscure.

In this study, 109 patient skin biopsies with histologically confirmed GA and localized scleroderma (morphea) were analysed retrospectively. The samples had been studied for the presence of *B. burgdorferi*, either because of a clinical suspicion of borreliosis or because of abundant plasma cells in the biopsy. In order to determine whether certain types of *Chlamydia*-related bacteria could play a role in the pathogenesis of these conditions, the occurrence and type(s) of *Chlamydiales* in the biopsies was examined, and the results compared with our previously published data on healthy skin and ticks (17). We recently reported the occurrence of *Chlamydiales* in up to 40% of Finnish ticks and, furthermore, in human skin biopsies. *Chlamydiales* DNA was found in human skin samples, with a prevalence of 49% in healthy skin (19/39, 49%) and 85% in skin samples from subjects positive for *B. burgdorferi* PCR. This suggests that ticks could indeed serve as vectors for transmission of *Chlamydia*-related bacteria.

MATERIALS AND METHODS

Patients

Data for all patients whose skin biopsies had a histology of GA or morphea and were submitted to *B. burgdorferi* DNA analysis

at the Department of Dermatology, Helsinki University Central Hospital from 2010 to 2015 were reviewed. The samples were studied for the presence of *B. burgdorferi* due to clinical suspicion of borreliosis, history of tick bites, or the dermatopathologist's recommendation based on histological features. The study included 109 skin biopsies from 73 patients with GA and 36 with morphea. Clinical and serological data were retrieved from patient files retrospectively.

Histopathology

Histopathological analysis was performed as routine investigation in the Laboratory of Dermatopathology, Skin and Allergy Hospital, Helsinki University Central Hospital by an experienced dermatopathologist. Histological slides were available for re-examination by one of the authors (LT) in 71 cases of GA and 34 cases of morphea.

GA has 2 predominant histological variants, palisading and interstitial, both of which are characterized by mucin and dermal inflammation (2). The histopathology of morphea is indistinguishable from the skin lesion of systemic sclerosis (3). The histopathological findings in the samples of our patients with GA and morphea were classic and identical to the description in standard textbooks.

Detection of *B. burgdorferi* in skin biopsies by PCR

B. burgdorferi sensu lato DNA detection was performed as a part of routine diagnostics by PCR amplification and hybridization with 16S rRNA- and *OspA*-specific primers and probes, as described earlier (6, 22). Real-time PCR with LightCycler® (Roche, Basel, Switzerland) was also performed. Briefly, PCR reactions contained 10 µl 2×MasterMix of the DyNAmo Flash Probe qPCR Kit (ThermoFisher Scientific, Waltham, MA, USA), 1 µl 10 µM the corresponding forward and reverse primers, 0.5 µl 10 µM probe,

Table I. Characteristics of 109 patients with granuloma annulare (GA) or morphea

	GA	Morphea
Patients, <i>n</i>	73	36
Male, <i>n</i> (%)	8 (11)	6 (17)
Female, <i>n</i> (%)	65 (89)	30 (83)
Age, years, mean (range)	59 (7–85)	55 (8–84)
Tick-bite recalled	17 (23)	7 (19)
Follow-up time, months, mean (range)	9 (0–55)	18 (0–55)
Localized disease, <i>n</i> (%)	38 (52)	20 (56)
Generalized disease, <i>n</i> (%)	35 (48)	16 (44)

and 100 ng template DNA in a total reaction volume of 20 µl. PCR cycling (60 cycles of 95°C 15 s, 60°C 1 min) was performed with a LightCycler instrument (Roche).

Borrelia antibodies

Anti-borrelia IgG and IgM antibodies were determined by 2 immunoassays. If the screening test (Genzyme Virotech GmbH, Russelsheim, Germany) was positive, a confirmatory chemiluminescence immunoassay (Liaison®) was performed as a routine procedure (Diasorin, Saluggia, Italy) by HUSLAB (23). The results were interpreted as described earlier (22).

Detection of *Chlamydia*-related bacteria in skin biopsies by PCR and sequencing of amplicons

Chlamydiales DNA was detected with a pan-*Chlamydiales* real-time TaqMan-PCR method, as described earlier (17, 24). Extreme precautions were taken to avoid cross-contamination, and no-template (water) controls were included in each PCR run. The resulting DNA amplicons (approximately 200 bp of the 16S rRNA gene region) were purified by Illustra ExoProStar



Fig. 1. Clinical pictures of granuloma annulare (GA) and morphea skin lesions. (A) Localized GA typically presents with an annular lesion on the dorsum of hand. (B) Generalized GA consisting of papules coalescing into plaques in certain regions. (C) Interstitial GA may present as an erythematous macule (upper arm). (D) Typical presentation of a wide patch of morphea.

1-Step (GE Healthcare, Buckinghamshire, UK) according to the manufacturer's instructions. Sequencing was then performed at the sequencing unit of the Institute for Molecular Medicine Finland.

BLAST analysis was performed in order to compare the obtained *Chlamydiales* sequences to the known sequences in the National Center for Biotechnology Information (NCBI) database, especially the *Chlamydiales* sequences from biopsies of healthy skin and from Finnish *Ixodes ricinus* ticks. For family-level classification, the first established *Chlamydiales* strain of the BLAST hit list was determined, and if the sequence identity was $\geq 90\%$, the 2 sequences were considered as members of the same *Chlamydiales* family (17, 25, 26).

RESULTS

Clinical and histological findings

Clinical characteristics of the patients are summarized in **Table I**. Most patients were female. The mean age of patients with GA was 59 years (range 7–85 years) and that of the patients with morphea was 55 years (range 8–84 years). Most of the patients did not recall having had a tick bite; and this has been reported even for patients with confirmed erythema migrans (22), since the very

Table II. Summary of histological findings

	Cases <i>n</i> (%)	Plasma cells		
		Negative <i>n</i> (%)	Sparse <i>n</i> (%)	Abundant <i>n</i> (%)
Granuloma annulare	71	31 (44)	31 (46)	7 (10)
Palisading pattern	44 (62)	23 (52)	20 (45)	1 (2)
Interstitial pattern	27 (38)	8 (30)	13 (48)	6 (22)
Morphea	34	3 (9)	18 (53)	13 (38)

tiny nymphs fall off the skin unnoticed after feeding. GA was localized in 38/73 (52%) and generalized in 35/73 (48%) of the patients (**Table I**, **Fig. 1**). Morphea was localized in 20/36 (56%) and generalized in 16/36 (44%) of the patients (**Table I**, **Fig. 1**).

Histological findings are summarized in **Table II** and visualized in **Fig. 2**. Of the GA cases, 38% were of the interstitial type. Plasma cells were present in 48% of the palisading GA cases and 70% of the interstitial GA cases. Of the morphea cases, plasma cells were present in 31/34 (91%). No correlation between the presence of plasma cells and positivity for either *Borrelia* or *Chlamydiales* DNA could be found in either group.




Fig. 2. Histology of granuloma annulare (GA) and morphea. (A) and (B) Palisading GA: central area of necrobiotic collagen and mucin surrounded by histiocytes, lymphocytes and giant cells. (C) Interstitial GA: histiocytes and lymphocytes are scattered around collagen bundles and blood vessels. Mucin is prominent. In this case plasma cells are present. (D) Histology of fibrotic stage morphea is characterized by tightly packed and eosinophilic collagen bundles, atrophic sweat glands and minimal inflammatory infiltrate. (Haematoxylin-eosin stain; original magnification: A and D $\times 4$; B $\times 10$; C $\times 20$).

Prevalence of *Borrelia* DNA

B. burgdorferi DNA was detected in 7/73 (9.6%) of the GA cases and 1/36 (2.8%) of the morphea cases. Unlike erythema migrans, lymphocytoma or acrodermatitis chronica atrophicans skin samples (27), 6/7 (85.7%) of the above GA biopsies and the single morphea sample were positive only for *ospA*. Only one GA sample was positive for both *ospA* and *16S rRNA* targets. Three of the 7 patients with GA had received oral antibiotics before our PCR determination (during the preceding year), which may have influenced the result. Most, 5/7 (71%), of the GA cases positive for *Borrelia* DNA were of the interstitial type.

Borrelia serology

Anti-borrelial antibodies were measured in 69 patients with GA and in 35 patients with morphea. The antibodies were defined positive in 8/69 (11%) cases of GA and in 4/35 (11%) cases of morphea. In addition, 7/69 (10%) patients with GA and 4/35 (11%) patients with morphea had borderline antibody titres.

The antibody levels did not correlate directly with the presence of *Borrelia*-specific DNA in the skin biopsies, since the only PCR-positive morphea patient and 3/7 (43%) of the PCR-positive GA patients had only borderline positive antibody reaction and the rest, 4/7 (57%) of the PCR-positive GA patients had negative serology.

Antibiotic treatments and their efficacy

All patients positive for *Borrelia* DNA received antibiotic treatment with amoxicillin, doxycycline or ceftriaxone with dosage recommended for *Borrelia* infections (27). Of the GA-cases positive for *Borrelia* DNA, 5/7 (71.4%) persisted regardless of adequate antibiotic therapy. One patient was cured with parenteral ceftriaxone treatment and one patient was lost to follow-up. The only morphea case positive for *Borrelia* DNA was cured with a course of amoxicillin and topical corticosteroid. In *Borrelia* PCR-negative cases, 40/67 (59.7%) of the GA lesions and 22/35 (62.9%) of the morphea lesions persisted until the end of the follow-up. The mean follow-up time was 9 months for GA and 18 months for morphea patients.

Prevalence and sequence analysis of *Chlamydia*-related bacteria detected in granuloma annulare and morphea skin biopsies

Chlamydiales DNA was detected by PCR in 53/73 (72.6%) of biopsies from lesions of GA, and in 25/34 (73.4%) of biopsies from morphea. Altogether 70 sequences were obtained (45 from GA and 25 from morphea). When possible, the sequences were classified by BLAST analysis to family level. In morphea lesions, most of the *Chlamydiales* sequences belonged to the families of Parachlamydiaceae (56%) and Criblamydiaceae (12%), while 23.5% remained unclassified. Within the GA group, a wider range of *Chlamydiales* sequences were detected: again, the most prevalent types were Parachlamydiaceae (24.4%) and Criblamydiaceae (15.6%), but in addition to those we detected members of Waddliaceae (11.1%), Rhabdochlamydiaceae (4.4%) and Chlamydiaceae (2.2%). Within the samples from GA, 42.2% of the *Chlamydiales* sequences could not be classified to the family level (Fig. 3).

All 7 GA skin biopsies positive for *Borrelia* DNA were also positive for *Chlamydiales* DNA. However, the single morphea patient positive for *Borrelia* DNA was negative when tested for *Chlamydiales* DNA.

Comparison of the *Chlamydiales* profile in GA and in morphea to those of healthy skin and *Ixodes ricinus* ticks (17)

The diversity of *Chlamydiales* sequences in skin lesions of morphea closely resembled that found in healthy skin (Fig. 3). However, in the GA lesions, the diversity was wider and also contained members of families Waddliaceae and Rhabdochlamydiaceae, also found in *Ixodes ricinus* ticks (Fig. 3).

DISCUSSION

This study is the largest of its kind on PCR and hybridization-based detection of *B. burgdorferi* in patients with GA. Also, it is the first to inspect *Chlamydiales* in GA and morphea. According to our results on the prevalence of *Borrelia* DNA, we propose that infections with *B.*




Fig. 3. *Chlamydiales* families in the sequenced pan-*Chlamydiales* PCR-positive skin biopsies from lesions of granuloma annulare (GA) and morphea, compared with those previously detected in *Ixodes ricinus* ticks and in biopsies of healthy skin (17).

burgdorferi can trigger GA in some cases, but the direct causal role seems unlikely. The prevalence of *Borrelia* DNA in our data was 9.6%, which is in accordance with the few previous studies (10). It is noteworthy that *Borrelia* DNA may persist in the skin for long time (28) and does not necessarily reflect an active *Borrelia* infection. However, in our retrospective study, the presence of *Borrelia* DNA was studied because of a clinical or histopathological suspicion of *Borrelia* infection. Thus, the prevalence in the whole spectrum of GA may be somewhat lower. Since all our GA patients positive for *Borrelia* DNA were treated with appropriate antibiotics and in at least 71.4% of the cases GA lesions persisted regardless of antibiotic treatment, *Borrelia* infection does not seem to be directly causative, but rather a triggering factor. This idea is supported by the finding that the antibody levels did not directly correlate with the presence of *Borrelia*-specific DNA. This is in accordance with the current literature (1). It could also be argued that the only *Borrelia* DNA positive GA patient whose GA lesions resolved after antibiotic treatment may have actually been a case of GA-like acrodermatitis chronica atrophicans. Four similar cases have been reported recently by French authors (29).

The prevalence of *B. burgdorferi* in morphea lesions has been studied much more than its correlation with GA. Most studies report a low or missing prevalence of *Borrelia* (10). Our result with a single case (2.8%) positive for *Borrelia* DNA is in accordance with previous studies. Because of the low prevalence, a causative or even triggering correlation between *Borrelia* infection and morphea is unlikely.

Members of the *Chlamydiales*, *Chlamydia*-related bacteria are naturally resistant to beta-lactam antibiotics, including amoxicillin and ceftriaxone used in the treatment of *Borrelia* infections. However, *Chlamydia*-related bacteria should be sensitive to doxycycline (30). In our study, 8 patients with GA positive for *Chlamydiales* DNA were treated with doxycycline, but none of them was cured. This speaks against a direct causative role of *Chlamydiales* in the pathogenesis of GA. Thus, only a triggering effect for GA is possible.

This study has some limitations. The clinical and serological data were retrieved retrospectively from the patient files, and thus the documentation or follow-up of patients was not standardized. The description of possible systemic symptoms was vague or absent in most of the cases, and the majority of patients with localized disease was not followed after initiation of treatment, mostly topical corticosteroid creams or ointments.

In conclusion, *Chlamydiales* DNA is frequently detected in skin lesion in GA and morphea. In GA, the *Chlamydiales* diversity differs from that in healthy skin and resembles the diversity observed in *Ixodes ricinus* ticks, suggesting a tick-derived origin. In morphea, however, the diversity of *Chlamydiales* sequences was

close to that in healthy skin. The occasional presence of *Borrelia* DNA and the tick-like *Chlamydiales* diversity in GA lesions combined with poor response to antibiotic treatment favours a possible triggering role of these tick-mediated infections in GA. Their correlation with morphea, however, is unlikely.

ACKNOWLEDGEMENTS

This study was supported by Biomedicum Helsinki Foundation, Academy of Finland (1285975) and Helsinki University Central Hospital Research Funds, Helsinki, Finland. The authors would like to thank Leila Jeskanen, MD, for histopathological analyses, and Allii Tallqvist, Kaija Järvinen and Anu Kaitonen for technical assistance.

REFERENCES

1. Piette EW, Rosenbach M. Granuloma annulare: pathogenesis, disease associations and triggers, and therapeutic options. *J Am Acad Dermatol* 2016; 75: 467–479.
2. Piette EW, Rosenbach M. Granuloma annulare: clinical and histologic variants, epidemiology, and genetics. *J Am Acad Dermatol* 2016; 75: 457–465.
3. Kreuter A. Localized scleroderma. *Dermatol Ther* 2012; 25: 135–147.
4. Saracino AM, Denton CP, Orteu CH. The molecular pathogenesis of morphea: from genetics to future treatment targets. *Br J Dermatol* 2017; 177: 34–46.
5. Knobler R, Moizadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, et al. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. *J Eur Acad Dermatol Venereol* 2017; 31: 1401–1424.
6. Ranki A, Aavik E, Peterson P, Schauman K, Nurmilaakso P. Successful amplification of DNA specific for Finnish *Borrelia burgdorferi* isolates in erythema chronicum migrans but not in circumscribed scleroderma lesions. *J Invest Dermatol* 1994; 102: 339–345.
7. Eisendle K, Grabner T, Zelger B. Morphea: a manifestation of infection with *Borrelia* species? *Br J Dermatol* 2007; 157: 1189–1198.
8. Ziemer M, Grabner T, Eisendle K, Baltaci M, Zelger B. Granuloma annulare – a manifestation of infection with *Borrelia*? *J Cutan Pathol* 2008; 35: 1050–1057.
9. Fernandez-Flores A, Ruzic-Sabljic E. Granuloma annulare displaying pseudorosettes in *Borrelia* infection. *Acta Dermatovenerol Alp Pannonica Adriat* 2008; 17: 171–176.
10. Zollinger T, Mertz KD, Schmid M, Schmitt A, Pfaltz M, Kempf W. *Borrelia* in granuloma annulare, morphea and lichen sclerosus: a PCR-based study and review of the literature. *J Cutan Pathol* 2010; 37: 571–577.
11. Valančienė G, Jasaitienė D, Valiukevičienė S. Pathogenesis and treatment modalities of localized scleroderma. *Medicina (Kaunas)* 2010; 46: 649–656.
12. Heyman P, Cochez C, Hofhuis A, van der Giessen J, Sprong H, Porter SR, et al. A clear and present danger: tick-borne diseases in Europe. *Expert Rev Anti Infect Ther* 2010; 8: 33–50.
13. Sormunen JJ, Penttinen R, Klemola T, Hanninen J, Vuorinen I, Laaksonen M, et al. Tick-borne bacterial pathogens in Southwestern Finland. *Parasit Vectors* 2016; 9: 168.
14. Karbowiak G, Biernat B. The role of particular tick developmental stages in the circulation of tick-borne pathogens affecting humans in central Europe. 2. Tick-borne encephalitis virus. *Ann Parasitol* 2016; 62: 3–9.
15. Swanson SJ, Neitzel D, Reed KD, Belongia EA. Coinfections acquired from *Ixodes* ticks. *Clin Microbiol Rev* 2006; 19: 708–727.

16. Burnard D, Weaver H, Gillett A, Loader J, Flanagan C, Polkinghorne A. Novel Chlamydiales genotypes identified in ticks from Australian wildlife. *Parasit Vectors* 2017; 10: 46.
17. Hokynar K, Sormunen JJ, Vesterinen EJ, Partio EK, Lilley T, Timonen V, et al. Chlamydia-like organisms (CLOs) in Finnish Ixodes ricinus ticks and human skin. *Microorganisms* 2016; 4: 28.
18. Pilloux L, Aeby S, Gümman R, Burri C, Beuret C, Greub G. The high prevalence and diversity of Chlamydiales DNA within Ixodes ricinus ticks suggest a role for ticks as reservoirs and vectors of Chlamydia-related bacteria. *Appl Environ Microbiol* 2015; 81: 8177–8182.
19. Croxatto A, Rieille N, Kernif T, Bitam I, Aeby S, Péter O, et al. Presence of Chlamydiales DNA in ticks and fleas suggests that ticks are carriers of Chlamydiae. *Ticks Tick Borne Dis* 2014; 5: 359–365.
20. Vouga M, Baud D, Greub G. Simkania negevensis, an insight into the biology and clinical importance of a novel member of the Chlamydiales order. *Crit Rev Microbiol* 2017; 43: 62–80.
21. Taylor-Brown A, Vaughan L, Greub G, Timms P, Polkinghorne A. Twenty years of research into Chlamydia-like organisms: a revolution in our understanding of the biology and pathogenicity of members of the phylum Chlamydiae. *Pathog Dis* 2015; 73: 1–122.
22. Eriksson P, Schröder MT, Niiranen K, Nevanlinna A, Panelius J, Ranki A. The many faces of solitary and multiple erythema migrans. *Acta Derm Venereol* 2013; 93: 693–700.
23. HUSLAB – Laboratory of Helsinki and Uusimaa Hospital District. *Borrelia burgdorferi, vasta-aineet seerumista*. 2012 [accessed 2012 May 31]. Available from: https://huslab.fi/cgi-bin/ohjekirja/tt_cgi.exe?hakulauseke=s-borrab&submit=hae&kenttavalinta=&rajoitus=lab.
24. Lienard J, Croxatto A, Aeby S, Jatton K, Posfay-Barbe K, Gervais A, et al. Development of a new chlamydiales-specific real-time PCR and its application to respiratory clinical samples. *J Clin Microbiol* 2011; 49: 2637–2642.
25. Everett KD, Bush RM, Andersen AA. Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identification of organisms. *Int J Syst Bacteriol* 1999; 49: 415–440.
26. Pillonel T, Bertelli C, Salamin N, Greub G. Taxogenomics of the order Chlamydiales. *Int J Syst Evol Microbiol* 2015; 65: 1381–1393.
27. Bacterial infections of the skin (online). Current care guidelines. Working group set up by the Finnish Medical Society Duodecim and The Finnish Dermatological Society. Helsinki: The Finnish Medical Society Duodecim, 2010 [accessed 2010 Nov 8]. Available from: www.kaypahoito.fi.
28. Yrjänäinen H, Hytönen J, Hartiala P, Oksi J, Viljanen MK. Persistence of borrelial DNA in the joints of *Borrelia burgdorferi*-infected mice after ceftriaxone treatment. *APMIS* 2010; 118: 665–667.
29. Lenormand C, Jaulhac B, Debarbieux S, Dupin N, Granel-Brocard F, Adamski H, et al. Expanding the clinicopathological spectrum of late cutaneous Lyme borreliosis (acrodermatitis chronica atrophicans [ACA]): a prospective study of 20 culture- and/or polymerase chain reaction (PCR)-documented cases. *J Am Acad Dermatol* 2016; 74: 685–692.
30. De Barys M, Bottinelli L, Greub G. Antibiotic susceptibility of *Estrella lausannensis*, a potential emerging pathogen. *Microbes Infect* 2014; 16: 746–754.